Physician profile
Kamal Batra
NPI 1245279462
$9,584.10
in general payments reported to CMS, 2019-2025
28 companies · $5,968 in 2025
The $5,968 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,074 · 2020: $537 · 2021: $119 · 2024: $886 · 2025: $5,968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,124 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,124.46 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $730.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,296.07 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Sanofi-Aventis U.S. LLC | $741.80 | 2024-2025 | |
| Corcept Therapeutics | $730.00 | 2025 | Korlym |
| Abbott Laboratories | $685.14 | 2019-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $626.86 | 2019-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Novo Nordisk INC | $562.24 | 2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $463.49 | 2024-2025 | Repatha, Tepezza, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $457.93 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $372.39 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $369.87 | 2019-2025 | Jardiance |
| Cequr Corporation | $276.59 | 2025 | Cequr Simplicity |
| Kowa Pharmaceuticals America, INC. | $231.44 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $211.49 | 2019 | |
| Amarin Pharma, INC. | $206.67 | 2019-2020 | |
| Abbvie INC. | $180.40 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $147.04 | 2025 | Ohtuvayre |
| Axsome Therapeutics, INC. | $125.00 | 2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $125.00 | 2024 | Gvoke Hypopen |
| Medtronic Vascular, INC. | $124.99 | 2019 | |
| Advanced Oxygen Therapy INC. | $122.49 | 2025 | Topical Oxygen Chamber For Extremities |
| Glaxosmithkline, LLC. | $121.35 | 2019 | |
| Ascendis Pharma Endocrinology INC | $119.62 | 2025 | Yorvipath |
| Janssen Pharmaceuticals, INC | $119.32 | 2021 | |
| Exact Sciences Corporation | $46.58 | 2025 | Cologuard Collection Kit |
| Medtronic, INC. | $35.01 | 2025 | Minimed 780g |
| Tandem Diabetes Care, INC. | $32.44 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Tactile Systems Technology INC | $26.83 | 2025 | Nimbl, Flexitouch Plus |
| Shield Therapeutics INC | $26.05 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamal Batra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.